Table 4.
Patient characteristics after about 20-month follow-up according to aortic stenosis classification
| AS classification | Alendronate treated | Nontreated | P# |
|---|---|---|---|
| Mild AS | |||
| n (%) | 13 (35.1) | 8 (24) | |
| NT-pro-BNP | 928.84±637.03 | 1101.37±534.82 | 0.53 |
| Delta-AVA | −0.08±0.21 | −0.21±0.11 | 0.12 |
| Nonmild AS | |||
| n (%) | 24 (64.8) | 25 (75.7) | |
| NT-pro-BNP | 855.83±457.12 | 1211.92±616.32 | 0.02 |
| Delta-AVA | −0.09±0.15 | −0.23±0.13 | 0.002 |
NT-Pro BNP=N-terminal-prohormone of brain natriuretic peptide; AVA=Aortic valve area; AS=Aortic stenosis. Data are expressed as frequency (%). #Based on Chi-square test